DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Tipifarnib is an investigational drug.
There have been 80 clinical trials for Tipifarnib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 1999.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and Kura Oncology, Inc.
Recent Clinical Trials for Tipifarnib
|Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial||National Cancer Institute (NCI)||Phase 2|
|Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy||Kura Oncology, Inc.||Phase 2|
|Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS||Spanish Lung Cancer Group||Phase 2|